Neuronetics (STIM) Projected to Post Quarterly Earnings on Tuesday

Neuronetics (NASDAQ:STIM) is anticipated to announce its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect the company to announce earnings of ($0.17) per share and revenue of $34.1680 million for the quarter. Investors may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.02. The business had revenue of $41.78 million during the quarter, compared to the consensus estimate of $40.84 million. Neuronetics had a negative net margin of 26.15% and a negative return on equity of 121.26%. On average, analysts expect Neuronetics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Neuronetics Price Performance

Shares of NASDAQ STIM opened at $2.02 on Monday. The company has a market cap of $140.55 million, a P/E ratio of -3.42 and a beta of 1.13. The firm has a 50-day simple moving average of $1.44 and a two-hundred day simple moving average of $1.72. Neuronetics has a 1 year low of $0.80 and a 1 year high of $4.85. The company has a debt-to-equity ratio of 2.51, a current ratio of 2.02 and a quick ratio of 1.87.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on STIM. Wall Street Zen raised shares of Neuronetics from a “sell” rating to a “hold” rating in a research report on Saturday, April 18th. Canaccord Genuity Group reduced their target price on shares of Neuronetics from $7.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, March 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $3.00.

Insider Buying and Selling

In related news, major shareholder Jorey Chernett bought 607,400 shares of Neuronetics stock in a transaction dated Wednesday, March 18th. The shares were acquired at an average cost of $1.35 per share, with a total value of $819,990.00. Following the completion of the transaction, the insider owned 8,123,804 shares in the company, valued at $10,967,135.40. The trade was a 8.08% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Keith J. Sullivan sold 46,289 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $1.34, for a total transaction of $62,027.26. Following the transaction, the director directly owned 1,590,924 shares in the company, valued at approximately $2,131,838.16. This trade represents a 2.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have bought 1,857,872 shares of company stock worth $2,431,406 and have sold 183,032 shares worth $269,588. Company insiders own 8.40% of the company’s stock.

Hedge Funds Weigh In On Neuronetics

Several institutional investors have recently bought and sold shares of STIM. UBS Group AG increased its holdings in Neuronetics by 580.7% during the third quarter. UBS Group AG now owns 2,164,831 shares of the company’s stock valued at $5,910,000 after buying an additional 1,846,801 shares during the period. Lane Generational LLC purchased a new position in Neuronetics during the fourth quarter valued at approximately $2,353,000. Goldman Sachs Group Inc. increased its holdings in Neuronetics by 2,993.3% during the first quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company’s stock valued at $2,320,000 after buying an additional 610,014 shares during the period. Geode Capital Management LLC increased its holdings in Neuronetics by 172.3% during the second quarter. Geode Capital Management LLC now owns 879,045 shares of the company’s stock valued at $3,068,000 after buying an additional 556,268 shares during the period. Finally, Wexford Capital LP increased its holdings in Neuronetics by 83.1% during the third quarter. Wexford Capital LP now owns 1,177,225 shares of the company’s stock valued at $3,214,000 after buying an additional 534,155 shares during the period. 53.59% of the stock is owned by hedge funds and other institutional investors.

About Neuronetics

Neuronetics, Inc is a commercial?stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.